Autres langues Walvax Biotechnology Co., Ltd.

Actions

300142

CNE100000WN2

Cours en clôture Shenzhen S.E. Autres places de cotation 00:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
14,33 ^CNY	+3,54 %		+2,43 %	-39,05 %

26/04	Le bénéfice de Walvax Biotechnology chute de 92%, le revenu d'exploitation glisse de 28% au premier trimestre 2024	MT
25/04	L'unité de Walvax Biotechnology met fin à l'essai du vaccin COVID-19	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Walvax Biotechnology's Profit Drops 92%, Operating Income Slids 28% in Q1 2024	26/04
Walvax Biotechnology's Unit to End COVID-19 Vaccine Trial	25/04
Walvax Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	24/04
China's drugmakers can't sell mRNA shots but haven't quit yet	19/04
Tranche Update on Walvax Biotechnology Co., Ltd.'s Equity Buyback Plan announced on April 5, 2023.	03/04
Walvax Biotechnology Co., Ltd.'s Equity Buyback announced on April 5, 2023, has expired with 2,000,000 shares, representing 0.12% for CNY 72.2 million.	03/04
Walvax Biotechnology's 2023 Profit Falls 42%	02/04
Walvax Biotechnology Co., Ltd. Proposes Cash Profit Distribution for 2023	01/04
Walvax Biotechnology Scraps Plan to Issue Convertible Bonds	01/04
Walvax Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Walvax Biotechnology Sees Up to 45% Drop in 2023 Profit	26/01
Chinese Shares End Mixed as Stimulus Hopes Fade; Walvax Falls 6% on Downbeat Profit Outlook	26/01
Zhifei Biological Falls After Merck Secures Nod to Market HPV Vaccine in China	11/01
Tranche Update on Walvax Biotechnology Co., Ltd.'s Equity Buyback Plan announced on April 5, 2023.	03/01
Lanvin Group Chief Executive Joann Cheng Steps Down	08/12
Walvax Biotechnology Registers Pneumonia Vaccines in Philippines	08/11
Walvax Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	25/10/23
Walvax Biotechnology's Unit Gets License to Market Pneumonia Vaccine in Indonesia; Shares Up 3%	24/10/23
Tranche Update on Walvax Biotechnology Co., Ltd.'s Equity Buyback Plan announced on April 5, 2023.	11/10/23
Walvax Biotechnology Unit Gets Nod to Carry Out Vaccine's Phase III Trial in Indonesia	20/09/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Walvax Biotechnology Co., Ltd.

Actions

300142

CNE100000WN2

Autres langues

Filtres